A Pilot Study of Urine Proteomics in COVID-19–Associated Acute Kidney Injury

Yinyin Ye1,6, Adam C. Swensen1,6, Yang Wang1, Madhurima Kaushal2, Diane Salamon2, Amanda Knoten2, Carrie D. Nicora1, Laura Marks2, Joseph P. Gaut3, Anitha Vijayan2, Daniel J. Orton1, Philip A. Mudd6, Chirag R. Parikh5, Wei-Jun Qian1, Jane A. O’Halloran2, Paul D. Piehowski1 and Sanjay Jain2,3

1Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA; 2Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; 3Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA; 4Department of Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; and 5Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Correspondence: Sanjay Jain, Department of Medicine (Nephrology), Kidney Translational Research Center, 660 South Euclid Avenue, MSC 8126-012-865, St. Louis, Missouri 63110, USA. E-mail: sanjayjain@wustl.edu; or Paul D. Piehowski, Pacific Northwest National Laboratory, Environmental and Molecular Sciences Division, 3335 Innovation Blvd, Richland, Washington 99354, USA. E-mail: paul.piehowski@pnnl.gov

6YY and ACS contributed equally to this work.

Received 21 April 2021; revised 17 August 2021; accepted 13 September 2021

© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

Acute kidney injury (AKI) is a major complication associated with COVID-19 and occurs in up to 76% of patients in the intensive care unit.1,2 The mortality rate of patients with COVID-19 who developed AKI (COVID-AKI) is >10 times higher than those who did not. Although candidate AKI markers exist, the etiology of COVID-AKI is multifactorial requiring agnostic approaches for identification of analytes early in hospital course to provide insights into biomarkers and mechanisms associated with COVID-AKI and COVID-19 infection.

Research on COVID-19–associated effects on the urinary proteome is limited, and kidney dysfunction has not been reported.3 Approximately 70% of the proteins detected in the urine are produced in the kidney with a significant amount filtered from the blood. We hypothesize that the changes in protein abundances in the urine could lead to the discovery of protein markers associated with COVID-19 or COVID-AKI and provide mechanistic insights to improve understanding.

RESULTS AND DISCUSSION

We analyzed urine samples from 14 participants (6 COVID-AKI, 3 COVID-no AKI, and 5 no COVID-no AKI) (Supplementary Materials and Methods, Supplementary Figure 1A and Supplementary Table S1). To account for the large variation in protein content across urine specimens, we used a bicinchoninic acid to measure peptide concentration after protein digestion (Supplementary Materials and Methods). All peptide samples are then normalized to the same concentration before the analysis to allow for relative quantitation of differences in the urinary proteome (Supplementary Materials and Methods).

The Urine Proteome of COVID-AKI

After confirming the quality of urine for analyte discovery (Supplementary Materials and Methods, Supplementary Table S2 and Supplementary Figure S1), we evaluated whether underlying variance could distinguish between AKI positive (AKI+) (6 COVID-AKI) from other samples without AKI (8 AKI negative): all AKI samples were from patients with COVID-19. The first 2 principal components accounted for 42.1% of the variance and clearly separated the 2 groups (Figure 1b), thereby suggesting a prominent impact by AKI on the urine proteome of patients with COVID-19. There was a statistically significant increase in 97 proteins and decrease in 140 proteins in the AKI+ group (adjP < 0.05; Figure 1c and Supplementary Figure S2A). Hierarchical clustering and pathway enrichment analysis revealed that the top up-regulated pathways were complement activation, coagulation cascades, and regulated exocytosis (Figure 1d and e).
Specifically, complement components C2, C3, C5, C6, and C8G were significantly increased in the AKI+ group affecting complement initiation (Figure 1d). Notably, decay-accelerating factor CD55 decreased 2.5-fold in the AKI+ group. This suggests reduced capacity to regulate complement activation, thereby exacerbating injury. This finding is supported by exacerbation of AKI in mice with deletion of CD55 after ischemia–reperfusion injury.4 Activation of the complement system is associated with severe COVID-19. The kidney cell protein sC5b-9, often associated with defective absorption by proximal tubules (FABP3, FABP4). A novel observation was a 3.6-fold increase in the urine owing to COVID-19. The MHC complex presents antigens at the cell surface to immune cells when cells are infected by viruses. MHC-peptide complexes have been detected in different human body fluids, including the serum and urine.6 The down-regulation of exocytosis was marked by the significantly decreased abundances of DEF5, GRN, HSPA6, SDCBP, IQGAP1, and CYRIB (Figure 2c).

Furthermore, there were 4 proteins with significantly increased abundances in COVID+ group compared with COVID− group, including MB, CA1, MNSCl, and ABRACL (Figure 2c and Supplementary Table S2 columns AA–AC). In addition, 5 proteins were significantly decreased in COVID+, including GRN, CREB3L3, MUC1, CD320, and DLST (Figure 2c and Supplementary Table S2 columns AA–AC). These newly identified proteins could potentially be used as more sensitive biomarkers to evaluate the COVID-19 infection. Moreover, the data reveal that several markers are extrarenal in COVID+ patients (Figure 2), including 5.68-fold increase in myoglobin (heart specific) and 3.92-fold increase in zymogen pepsinogen C (lung, esophagus, and stomach injury), which are promising targets for noninvasive urine proteome
Table 1. Characteristics and laboratory data of urine samples and donors, PCA separation, significant proteins, and affected pathways associated with COVID-AKI. (a) Characteristics and laboratory data of the study participants. The patient key is provided in the leftmost column. (b) The impact of COVID-AKI on the urinary proteome. PCA plot of urine proteomics data annotated with subject AKI status; note, all AKI+ patients had COVID-19. Patient key numbers provided for identification. (c) Volcano plot of the log2 fold changes of protein abundances and their statistical significance in urine owing to AKI status. The dashed line indicates adjusted $P = 0.05$. (d) Heatmap of select urine proteins in AKI+ and AKI− groups. The **+** denotes patients with COVID-19 infected with SARS-CoV-2. The protein abundances (each row displayed as Z-score) were significantly changed owing to the AKI (limma test, adjusted $P < 0.05$). (e) The enriched reactome pathways, KEGG pathways, or GO BP were displayed for down-regulation (light gray) and up-regulation (dark gray) in the urine of patients with COVID-19 with AKI. AKI, acute kidney injury; AKI−, acute kidney injury negative; AKI+, acute kidney injury positive; COVID-AKI, AKI owing to COVID-19; GO BP, Gene Ontology biological processes; KEGG, Kyoto Encyclopedia of Genes and Genomes; PC, principal component; PCA, principal component analysis.

<table>
<thead>
<tr>
<th>Patient Key</th>
<th>Sample ID</th>
<th>Age</th>
<th>Race</th>
<th>Gender</th>
<th>SARS-CoV-2 positive</th>
<th>AKI Status</th>
<th>Serum Creatinine (mg/dl)</th>
<th>Comorbidity</th>
<th>Mortality status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>077_D0</td>
<td>70-79</td>
<td>Black</td>
<td>Male</td>
<td>Yes</td>
<td>AKI pos</td>
<td>2.20</td>
<td>CKD</td>
<td>Deceased</td>
</tr>
<tr>
<td>2</td>
<td>078_D0</td>
<td>20-29</td>
<td>White</td>
<td>Female</td>
<td>No</td>
<td>AKI neg</td>
<td>0.67</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>080_D0</td>
<td>80-89</td>
<td>Black</td>
<td>Male</td>
<td>Yes</td>
<td>AKI pos</td>
<td>1.58</td>
<td>alive</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>083_D0</td>
<td>70-79</td>
<td>Black</td>
<td>Male</td>
<td>Yes</td>
<td>AKI pos</td>
<td>1.75</td>
<td>CKD</td>
<td>Deceased</td>
</tr>
<tr>
<td>5</td>
<td>086_D0</td>
<td>40-49</td>
<td>Black</td>
<td>Female</td>
<td>Yes</td>
<td>AKI neg</td>
<td>0.89</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>087_D0</td>
<td>60-69</td>
<td>Black</td>
<td>Male</td>
<td>Yes</td>
<td>AKI pos</td>
<td>2.92</td>
<td>alive</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>090_D0</td>
<td>60-69</td>
<td>Black</td>
<td>Male</td>
<td>Yes</td>
<td>AKI neg</td>
<td>1.14</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>093_D0</td>
<td>80-89</td>
<td>White</td>
<td>Male</td>
<td>Yes</td>
<td>AKI pos</td>
<td>1.97</td>
<td>CKD</td>
<td>Deceased</td>
</tr>
<tr>
<td>9</td>
<td>102_D0</td>
<td>20-29</td>
<td>Black</td>
<td>Male</td>
<td>Yes</td>
<td>AKI neg</td>
<td>1.32</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>114_D0</td>
<td>40-49</td>
<td>Black</td>
<td>Male</td>
<td>No</td>
<td>AKI neg</td>
<td>1.12</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>117_D3</td>
<td>50-59</td>
<td>White</td>
<td>Male</td>
<td>Yes</td>
<td>AKI pos</td>
<td>3.70</td>
<td>CKD</td>
<td>Deceased</td>
</tr>
<tr>
<td>12</td>
<td>133_D0</td>
<td>20-29</td>
<td>Black</td>
<td>Female</td>
<td>No</td>
<td>AKI neg</td>
<td>0.99</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>K200129P</td>
<td>50-59</td>
<td>Asian</td>
<td>Male</td>
<td>No</td>
<td>AKI neg</td>
<td>0.76</td>
<td>Alive</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>K200128P</td>
<td>60-69</td>
<td>White</td>
<td>Female</td>
<td>No</td>
<td>AKI neg</td>
<td>0.70</td>
<td>Alive</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Characteristics and laboratory data of urine samples and donors, PCA separation, significant proteins, and affected pathways associated with COVID-AKI. (a) Characteristics and laboratory data of the study participants. The patient key is provided in the leftmost column. (b) The impact of COVID-AKI on the urinary proteome. PCA plot of urine proteomics data annotated with subject AKI status; note, all AKI+ patients had COVID-19. Patient key numbers provided for identification. (c) Volcano plot of the log2 fold changes of protein abundances and their statistical significance in urine owing to AKI status. The dashed line indicates adjusted $P = 0.05$. (d) Heatmap of select urine proteins in AKI+ and AKI− groups. The **+** denotes patients with COVID-19 infected with SARS-CoV-2. The protein abundances (each row displayed as Z-score) were significantly changed owing to the AKI (limma test, adjusted $P < 0.05$). (e) The enriched reactome pathways, KEGG pathways, or GO BP were displayed for down-regulation (light gray) and up-regulation (dark gray) in the urine of patients with COVID-19 with AKI. AKI, acute kidney injury; AKI−, acute kidney injury negative; AKI+, acute kidney injury positive; COVID-AKI, AKI owing to COVID-19; GO BP, Gene Ontology biological processes; KEGG, Kyoto Encyclopedia of Genes and Genomes; PC, principal component; PCA, principal component analysis.
profiling to detect and monitor kidney-independent organ damage.

The SARS-CoV-2 virion is not typically shed in the urine, but it has tropism to kidney cell types. We evaluated whether urine proteomics can detect SARS-CoV-2 proteins. Interestingly, peptides from SARS-CoV-2 nucleoprotein were detected in the urine samples collected from 2 severely ill patients with COVID-AKI who died (Supplementary Materials and Methods, Figure 1a and Supplementary Table S1). The peptide identification was confirmed by searching with both MaxQuant and MS-GF+ software. Near-complete sequence coverage of the RNA binding domain was achieved by single dimension liquid chromatography coupled to tandem mass spectrometry analysis. Sequences near the N-terminus of the SARS-CoV-2 nucleoprotein were also observed (Figure 2d). Owing to the relatively low-count peptide-spectrum matches of SARS-CoV-2 peptides observed, the concentration of SARS-CoV-2 nucleoprotein is predicted to be low in these urine samples (Supplementary Table S3).

Although our study is a proof-of-concept investigation with a relatively small number of patient samples, we were able to establish methods for high-quality urine proteomics of patients with COVID-19 in a clinical setting. We report potential biomarkers of COVID-19 infection and COVID-AKI which could be useful for detecting and monitoring kidney-independent organ damage.

Figure 2. The impact of COVID-19 infections on the urinary proteome. The urine donors were all negative for AKI. (a) Volcano plot of the log₂ fold changes of protein abundances and their statistical significance owing to COVID-19 infections. The dashed line indicates adjusting $P = 0.05$. (b) Up-regulated (dark gray) and down-regulated (light gray) reactome pathways GO BP enriched owing to COVID-19 infections. (c) Heatmap of selected urinary proteins that displayed increased or decreased abundances in urine owing to COVID-19 (limma test, adjusting $P < 0.05$). (d) Sequence coverage of SARS-CoV-2 nucleoprotein. Peptides of SARS-CoV-2 proteins were detected in 2 urine samples. The 2 patients developed acute kidney injury along with severe COVID-19 symptoms. Details of peptide sequences were summarized in Supplementary Table S2. AKI, acute kidney injury; GO BP, Gene Ontology biological processes.
monitoring the development of COVID-19 infection or AKI. In particular, the complement and coagulation cascade pathways and exocytosis pathway were highly up-regulated in the patients with COVID-AKI. Furthermore, proteins associated with antigen presentation were significantly correlated with COVID-19 infection. We propose a list of potential novel biomarker proteins (i.e., MB, CA1, MANSC1, ABRACL, GRN, CREB3L3, DEFA1, MUC1, DLST, and IGFBP6) and of previously reported AKI biomarker proteins (i.e., NGAL, FABP3, FABP4, MEP1A, and RBP4) for further validation of their specificity, sensitivity, and severity. A subset of our patients with COVID-AKI developed AKI on preexisting chronic kidney disease, which could also affect the urine proteins found enriched in this group. Parsing the effect of chronic kidney disease status in COVID-19 would require larger cohorts; however, we observe that the enrichment of complement and coagulation pathway proteins was found in the patients with COVID-AKI with and without chronic kidney disease (Figure 1d and Supplementary Table S1). Taken together, these exciting preliminary results clearly reveal the need for further investigation in an expanded clinical cohort that includes patients with non–COVID-19-associated AKI.

**DISCLOSURE**

CRP reports being a member of the advisory board of and owning equity in Renalytix AI and serving as a consultant for Genfit. AV reports serving as a consultant for NxStage Medical Inc. and Astute Medical Inc. These entities did not support research in this study. All the other authors declared no competing interest.

**ACKNOWLEDGMENTS**

This study used samples obtained from the COVID-19 biorepository of the Washington University School of Medicine, which is supported by the following: the Barnes-Jewish Hospital Foundation; the Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National Institutes of Health; and the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. We thank the George M. O’Brien Center of the Johns Hopkins University for performing the kidney injury biomarker assays (grant #P30DK079310). Parts of this research were performed using EMSL, a national scientific user facility sponsored by the Department of Energy’s Office of Biological and Environmental Research and located at PNNL. The proteomics work is supported by NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under award UG3HL145593, and NIH grant U01DK124020. The content is solely the responsibility of the authors and does not necessarily represent the view of the National Institutes of Health. We thank the Kidney Translational Research Center (KTRC) of the Division of Nephrology at the Washington University in St. Louis for supporting the processing, preservation, and storage of the urine samples. We are grateful to Charles Goss, Adriana Rauseo Acevedo, and Rachel Presti for their efforts in data management and patient recruitments. We also thank Jana Chiang for her contributions in editing, formatting, and reviewing the content.

**SUPPLEMENTARY MATERIAL**

**Supplementary File (PDF)**

**Supplementary Materials and Methods.** Includes information on the methods used for sample acquisition and patient inclusion, urine processing and storage, proteomics sample preparation, LC-MS/MS-based proteomics analysis, proteomics data processing, correlation analysis of patients with COV-AKI compared with those without AKI, and where the data are available to download.

**Figure S1.** Pearson correlation of urinary proteomics across the studied samples.

**Figure S2.** Distribution of P values before adjustment. (A) Statistical results of limma test that compared the intensities of urine proteins based on the status of acute kidney injury (AKI). (B) Statistical results of limma test that compared the intensities of urine proteins based on the COVID-19 infection in the AKI-negative group.

**Table S1.** Master sheet of research participants.

**Table S2.** Statistical analysis results of urinary proteomics.

**Table S3.** SARS-CoV-2 peptides detected in 2 urine samples by LC-MS/MS. The proteomics data were searched with MSGF+ software.

**STROBE Statement (PDF).**

**REFERENCES**


